| BioVersys | AMR Action Fund, GSK, private Investoren | 200 Mio. Fr. | | Citi, UBS, Stifel | 1. Q. 2025 |
|---|
| Spineart | Management, EGS, weitere | 300–400 Mio. Fr. | | UBS | 1. HJ. 2025 |
|---|
| SMG | TX Group, Ringier, Mobiliar, General Atlantic | 3–4 Mrd. Fr. | Evercore, Rothschild | | 2. HJ. 2025 |
|---|
| Ammega | Partners Group | 3–3,5 Mrd. Fr. | | Bank of America, UBS | 2. HJ. 2025 |
|---|
| Acrotec | Carlyle | 2,5–3,5 Mrd. Fr. | Rothschild | UBS, Morgan Stanley, Bank of America | 2. HJ. 2025 |
|---|
| Syntegon | CVC | 3–4 Mrd. Fr. | | UBS | 2. HJ. 2025 |
|---|
| Corden Pharma | Astorg | 3–4 Mrd. Fr. | | | 2. HJ. 2025 |
|---|
| VFS Global | Temasek, Blackstone, EQT, Kuoni und Hugentobler-Stiftung | > 5 Mrd. Fr. | | | 2026 |
|---|
| Swissport | mehrere Private Equity | | | | 2026 |
|---|
| Gategroup | Temasek, RRJ Capital | | | | 2026 |
|---|
| Breitling | Partners Group, CVC | | | | offen |
|---|
| ABB E-Mobility | ABB, General Atlantic, GIC, Just Climate, Porsche | > 3 Mrd. Fr. | | | offen |
|---|